Búsqueda en vivo
TopFind está obteniendo las coincidencias más recientes para tu búsqueda.
Revisamos 617 resultados en vivo para skyrizi risankizumab sdn bhd y los redujimos a 3 opciones que parecen valer más la pena comparar primero.
Los temas más fuertes en esta lista son Biologics y Immunology.
Fuente: AbbVie Malaysia
Descripción
The Malaysian-market specific supply of Skyrizi, indicated for moderate-to-severe plaque psoriasis and related conditions. It is provided through hospital-based clinical channels and specialized pharmacies.
Ideal para
Malaysian medical services, Psoriasis treatment y Rheumatology care
Valoración
Fuente: AbbVie Singapore
Descripción
Prescription biologic for the treatment of plaque psoriasis and psoriatic arthritis. The Singapore hub serves as a key regional reference for medical documentation and treatment guidelines for risankizumab therapies in Southeast Asia.
Ideal para
Regional medical reference, Singapore Based patients y Biologic therapy information
Valoración
Fuente: AbbVie Pharmaceuticals (Thailand) Ltd.
Descripción
Skyrizi (risankizumab) is a prescription biological medication used to treat adults with moderate-to-severe plaque psoriasis, psoriatic arthritis, and Crohn's disease. As an IL-23 inhibitor, it targets the p19 subunit to manage chronic inflammation and is administered via subcutaneous injection, typically requiring a maintenance dose every 12 weeks after initial loading.
Ideal para
Plaque psoriasis patients, Psoriatic arthritis management, Crohn's disease treatment y Long Term biologic therapy
Valoración
| Comparar | Skyrizi (risankizumab) Sdn Bhd | Skyrizi (risankizumab) 150mg | Skyrizi (risankizumab) |
|---|---|---|---|
| Fuente | AbbVie Malaysia | AbbVie Singapore | AbbVie Pharmaceuticals (Thailand) Ltd. |
| Descripción | The Malaysian-market specific supply of Skyrizi, indicated for moderate-to-severe plaque psoriasis and related conditions. It is provided through hospital-based clinical channels and specialized pharmacies. | Prescription biologic for the treatment of plaque psoriasis and psoriatic arthritis. The Singapore hub serves as a key regional reference for medical documentation and treatment guidelines for risankizumab therapies in Southeast Asia. | Skyrizi (risankizumab) is a prescription biological medication used to treat adults with moderate-to-severe plaque psoriasis, psoriatic arthritis, and Crohn's disease. As an IL-23 inhibitor, it targets the p19 subunit to manage chronic inflammation and is administered via subcutaneous injection, typically requiring a maintenance dose every 12 weeks after initial loading. |
| Ideal para | Malaysian medical services, Psoriasis treatment y Rheumatology care | Regional medical reference, Singapore Based patients y Biologic therapy information | Plaque psoriasis patients, Psoriatic arthritis management, Crohn's disease treatment y Long Term biologic therapy |
| Acción | |||
| Valoración |
Si quieres empezar con la opción más equilibrada, te recomiendo:
"Skyrizi (risankizumab) Sdn Bhd de AbbVie Malaysia."
Lo elegí porque Ensures access to the authentic IL-23 inhibitor within Malaysia's pharmaceutical regulatory framework.